As the Director of Hematology/Oncology Project Management at PPD, Sarah R. leverages her extensive global clinical research and development experience to drive innovative solutions in early-phase oncology research, particularly in the rapidly evolving fields of cell and gene therapy, including CAR-T therapies. With a robust...
As the Director of Hematology/Oncology Project Management at PPD, Sarah R. leverages her extensive global clinical research and development experience to drive innovative solutions in early-phase oncology research, particularly in the rapidly evolving fields of cell and gene therapy, including CAR-T therapies. With a robust background in both biotech and large pharmaceutical environments, Sarah has honed her expertise in strategic portfolio oversight, ensuring that projects align with the latest advancements in hematology and oncology therapeutics.
In her current role, Sarah is accountable for managing a diverse portfolio of clinical trials, focusing on the complexities and regulatory challenges inherent in hematology and oncology research. Her leadership extends beyond project oversight; she actively cultivates a high-performing team, fostering an environment of collaboration and innovation. Her experience embedded within a pharmaceutical company via a Functional Service Provider (FSP) model has equipped her with a unique perspective on operational efficiencies and cross-functional integration, enhancing her ability to navigate the intricate landscape of clinical trial management.
Sarah's proficiency in Good Clinical Practice (GCP) and Clinical Trial Management Systems (CTMS) ensures that her projects not only meet regulatory standards but also achieve optimal outcomes for patients. Her comprehensive understanding of various therapeutic areas, including gastroenterology, dermatology, and infectious diseases, complements her hematology and oncology focus, allowing her to approach challenges with a well-rounded perspective. As she continues to lead pivotal projects in cell and gene therapy, Sarah remains dedicated to advancing the frontiers of oncology research, ultimately aiming to improve patient outcomes and contribute to the future of cancer treatment.
